drugset
drugset / Trial / NCT06105151

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

NCT06105151 ↗

Phase 1 Recruiting 82 enrolled Vigonvita Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study

Timeline

Start
2023-10-27
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VV119 Unknown 0.2 mg Oral
Subject VV119 Unknown 0.5 mg Oral
Subject VV119 Unknown 1 mg Oral
Subject VV119 Unknown 2 mg Oral
Subject VV119 Unknown 3 mg Oral
Subject VV119 Unknown 4.5 mg Oral
Subject VV119 Unknown 6 mg Oral
Subject VV119 Unknown 8 mg Oral
Subject VV119 Unknown 10 mg Oral

Indications

schizophrenia